Vinati Organics Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/k9rszw47qzakz6z9lrzsdwk4.pdf

Key Takeaways


ATBS: Demand, Capacity & the Growth Bet

Vinati Saraf Mutreja: "I would personally expect, say, 15% volume growth year-on-year, at least for the next 3 years and which would take care of our expansion."

Portfolio Headwinds & Recoveries

Vinati Saraf Mutreja: "I believe in the period, about 80% or 90% applications of ADD were rejected and the Ministry of Commerce is in talks with the Ministry of Finance to give an explanation. Nevertheless, we have reapplied."

New Products & the Pipeline

Vinati Saraf Mutreja: "Most of them, I think what's important, they are niche chemicals. We are targeting niche chemicals going forward."

Margins & the Long-Term Reset

Vinati Saraf Mutreja: "I think I've maintained an EBITDA margin of 26% to 27% because given expansions, new products, raw material fluctuations, I think that's a reasonably achievable EBITDA margin on a long-term basis."

Sector Dynamics & Competitive Landscape


Guidance & Commitments

CommitmentSpecificsTimeline
ATBS volume growth~15–20% YoYFY27
ATBS volume growth15% YoY at leastNext 3 years
Company-level volume growth~15%FY27
ATBS Phase 2 expansionCommissioningOctober FY27
VOPL production restartPost-reengineering completionOctober FY27 (revenue from Q3)
VOPL revenue₹100–120 crPost-reengineering, from FY27 Q3 onward
MEHQ / Guaiacol revenue~₹100 crFY27
New products (2–3)LaunchH2 FY27, revenues in FY28
Antioxidants + butyl phenol revenue₹800–900 crNext 2 years
Annual capex₹250–300 crNext 3–5 years
FY27 capex₹200–250 crFY27
Value-added products capex~₹250 crOngoing
Long-term EBITDA margin26–27%Long-term basis
ADD on antioxidantsDecision timeline6–9 months from reapplication, if successful

Key Metrics

MetricQ4 FY26
Standalone net income (incl. other income)₹631 cr, up 17% QoQ from ₹538 cr
Standalone EBITDA₹203 cr, up 20% QoQ from ₹169 cr
Standalone PAT₹137 cr, up 27% QoQ from ₹108 cr
Consolidated net income (incl. other income)₹624 cr, up 16% QoQ from ₹540 cr
Consolidated EBITDA₹191 cr, up 15% QoQ from ₹165 cr
Consolidated PAT₹123 cr, up 23% QoQ from ₹101 cr
FY26 standalone net income (incl. other income)₹2,281 cr, stable vs FY25
FY26 standalone EBITDA₹741 cr, up 17% from ₹630 cr in FY25
FY26 standalone PAT₹488 cr, up 18% from ₹415 cr in FY25
FY26 consolidated net income (incl. other income)₹2,280 cr, stable vs FY25
FY26 consolidated EBITDA₹707 cr, up 13% from ₹625 cr in FY25
FY26 consolidated PAT₹444 cr, up 9% from ₹405 cr in FY25
ATBS volume growth outlook (FY27)15% to 20%, recovery expected after demand softened from October 2025
Company-level volume growth target (FY27)~15%
ATBS capacity utilization~80%, 75% even after expansion
Butyl phenol capacity utilization70% to 75%
IBB volume decline (FY26 vs FY25)~20%, partly due to raw material unavailability from Iran war
Customized products segment growth (FY26)10% YoY
Antioxidants revenue growth (FY26)15%, despite challenging market environment
FY26 capex incurred~₹270 cr, including VOPL investments
FY27 capex projection₹200 cr to ₹250 cr, of which ₹40-50 cr in VOPL, ₹200 cr in main holding company
Treasury as of March 31, 2026~₹190 cr
Dividend recommended for FY26₹8.50 per equity share of face value ₹1
VOPL revenue in FY26~₹10 cr, hardly any sale
VOPL expected revenue (FY27)₹100 cr to ₹120 cr, after reengineering, from Q3 onwards
ATBS capacity (lower molecular weight)50,000 tonnes; 40,000 tonnes for higher purity; each phase 10,000 tonnes
ATBS Phase 1 and Phase 2 combined capex₹250 cr to ₹300 cr
CWIP at year-end~₹210 cr; ₹60-70 cr yet to be capitalized under VOPL, ₹120-125 cr in VOPL to be capitalized in FY27
Antioxidants plus butyl phenol revenue target₹800 cr to ₹900 cr, to be achieved in next 2 years
Long-term EBITDA margin outlook26% to 27%
Annual capex expectation (next 3-5 years)₹250 cr to ₹300 cr